Evidence map›Paper›PMID 35283644›Full record

Trial reportCancer management and research2022

Jianhao Xie, XueYu Yuan, Weiqing Mao, Haidong Cai, Kejia Gao, Zhongwei Lv, Hui Wang, Chao Ma

Open access · goldAbstract readCase ReportsClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer management and research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Frontiers in endocrinology · 2025
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Jianhao Xie *Department of Nuclear Medicine, Tenth People's Hospital of Tongji University, Shanghai, People's Republic of China.
XueYu Yuan *Department of Nuclear Medicine, Tenth People's Hospital of Tongji University, Shanghai, People's Republic of China.
Weiqing Mao *Department of Nuclear Medicine, Tenth People's Hospital of Tongji University, Shanghai, People's Republic of China.
Haidong CaiDepartment of Nuclear Medicine, Tenth People's Hospital of Tongji University, Shanghai, People's Republic of China.
Kejia GaoDepartment of Nuclear Medicine, Shanghai No. 4 People's Hospital, Shanghai, People's Republic of China.
Zhongwei LvDepartment of Nuclear Medicine, Tenth People's Hospital of Tongji University, Shanghai, People's Republic of China.
Hui WangDepartment of Nuclear Medicine, Xinhua Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, People's Republic of China.
Chao MaDepartment of Nuclear Medicine, Tenth People's Hospital of Tongji University, Shanghai, People's Republic of China.
Tongji University · CNShanghai Tenth People's Hospital · CNBeijing Jishuitan Hospital · CNXinHua Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To investigate the effects of Patients and Methods: Patients (n = 142) were divided into two groups: (1) Results: The percentage change of BMD in total lumbar spine or hip showed no significant difference throughout the study (P > 0.025). Conclusion:

Indexed as

99Tc-MDPdifferentiated thyroid cancerosteoporosisthyroid stimulating hormone suppression

Identifiers

PMID35283644
PMCPMC8906701
OpenAlexW4214881011

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.